Friday, 18 Oct 2019

You are here

Angiogenic Biomarkers Predict Adverse Outcomes Pregnancies in Lupus

The PROMISSE (Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus) study has revealed several important lessons in lupus care.

Earlier reports showed that those in remission or minimal activity had a favorable outcome with 82% uncomplicated pregnancies. The 4 features shown to predict poor outcomes included lLupus anticoagulant positivity: OR 8.32 (95% CI 3.59-19.26), antihypertensive drug use (OR 7.05; 95% CI 3.05-16.31), physician's global assessment > 1 (OR 4.02; 95% CI 1.84-8.82, P<0.001) and a low platelet count (OR 1.33; 95% CI 1.09-1.63).

Another analysis of predictive vascular biomarkers studied 497 pregnant SLE patients or APL who were enrolled at <12 weeks gestation (before end of the 1st trimester) and followed them monthly along with 207 matched healthy controls. Serial assays for several circulating vascular biomarkers were done including soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF) and soluble endoglin (sEng).

These results were compared to the frequene of adverse pregnancy outcomes (APO), defined as as severe (PE<34 weeks, fetal/neonatal death, indicated pre-term delivery <30 weeks) or moderate (PE≥34 weeks, indicated preterm delivery 30-36 weeks, growth restriction without PE).

Severe APOs occurred in 12% and moderate APOs in 10% of patients. By 12-15 weeks, sFlt1, PlGF, and sEng levels were markedly altered in women who developed severe APO. sFlt1 was the strongest predictor of severe APO among 12-15 week measures (adjusted odds ratio=17.3 comparing highest and lowest quartiles, 95% CI: 3.5-84.8) with a positive predictive value (PPV) of 61% and negative predictive value (NPV) of 93%. At 16-19 weeks, the combination of sFlt1 and PlGF was most predictive of severe APO, with risk greatest for subjects with both PlGF in lowest quartile (<70.3 pg/ml) and sFlt1 in highest quartile (>1872 pg/ml; odds ratio=31.1; 95% CI: 8.0-121.9; PPV=58%; NPV=95%).

Severe APO rate in this high risk subgroup was 94% (95%CI: 70%-99.8%), if lupus anticoagulant or history of high blood pressure is additionally present.  Thos patients with low values for both sFlt1 <1872 pg/ml and PlGF >70.3 pg/ml, rate of severe APO was only 4.6% (95% CI: 2.1%- 8.6%).

The abscence of circulating angiogenic factors in early gestation have a high negative predictive value in ruling out the development of severe adverse pregnancy outcomes among patients with SLE and/or APL syndrome.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.

Serum Interferon Predicts Lupus Flares

Elevated serum levels of interferon-α among patients whose systemic lupus erythematosus (SLE) was in remission helped predict future disease flares, European researchers found.

Among 254 SLE patients who were in remission, 26% had abnormally high serum levels of interferon-α at baseline, according to Alexis Mathian, MD, of Pitié-Salpêtrière Hospital in Paris, and colleagues.